Compassionate use of cefiderocol for carbapenem-resistant Acinetobacter baumannii prosthetic joint infection
Open Access
- 1 June 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 3 (Supplement) , i21-i24
Abstract
Cefiderocol is a recently licensed novel siderophore-conjugated cephalosporin stable to hydrolysis by serine and MBLs. It has been successfully used to treat Enterobacterales infections and is approved for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options. To describe the compassionate use of cefiderocol and clinical outcome in a case of prosthetic joint infection due to MDR Acinetobacter baumannii. This case study follows a 66-year-old woman who sustained an open fracture of the left distal humerus in Pakistan. She underwent open reduction and internal fixation and on return to the UK presented to hospital with a discharging surgical wound. Debridement of her wound cultured NDM carbapenemase-producing A. baumannii susceptible to colistin, tobramycin and tigecycline only. She developed vomiting with acute kidney injury with colistin and tigecycline. Antimicrobial efficacy of cefiderocol was predicted from in vitro and in vivo susceptibility tests. A successful request was made to Shionogi for compassionate use of cefiderocol, which was added to tigecycline. Cefiderocol was well tolerated with no toxicity and improved renal function. In total she received 25 days of cefiderocol and continued on tigecycline for a further 6 weeks in the community. She has well-healed wounds and good range of elbow movement. Cefiderocol’s novel mode of cell entry is effective against MDR Gram-negative bacteria with reduced toxicity compared with other last line antibiotics. Our case demonstrates that cefiderocol may be useful as therapy for patients with limited treatment options due to antimicrobial resistance. The prescribing information for cefiderocol is available at: https://shionogi-eu-content.com/gb/fetcroja/pi.Keywords
Funding Information
- Queen Mary University of London
This publication has 19 references indexed in Scilit:
- Dissemination of blaOXA-23-harbouring carbapenem-resistant Acinetobacter baumannii clones in PakistanJournal of Global Antimicrobial Resistance, 2020
- Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore CephalosporinClinical Infectious Diseases, 2019
- In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative BacteriaClinical Infectious Diseases, 2019
- Comparative Analysis of the Two Acinetobacter baumannii Multilocus Sequence Typing (MLST) SchemesFrontiers in Microbiology, 2019
- Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative BacilliDrugs, 2019
- Emergence of carbapenem-resistant Acinetobacter baumannii in hospitals in PakistanJournal of Medical Microbiology, 2014
- Global evolution of multidrug-resistant Acinetobacter baumannii clonal lineagesInternational Journal of Antimicrobial Agents, 2013
- In Vivo Efficacy of Glycopeptide-Colistin Combination Therapies in a Galleria mellonella Model of Acinetobacter baumannii InfectionAntimicrobial Agents and Chemotherapy, 2011
- Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistanceInternational Journal of Antimicrobial Agents, 2010
- Acinetobacter baumanniiSkin and Soft‐Tissue Infection Associated with War TraumaClinical Infectious Diseases, 2008